Drug recall · February 12, 2020
Pioglitazone and Metformin Hydrochloride Tablets recall
Why: Subpotent Drug: Out of specification assay result, below specification, for two lots of Pioglitazone And Metformin Hydrochloride Tablets.
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
Pioglitazone and Metformin Hydrochloride Tablets, USP 15 mg/500 mg, Rx Only, 60-count bottle, Manufactured for Macleods Pharma USA, Inc. Plainsboro, NJ 08536, Manufactured by: Macleods Pharmaceuticals Ltd. Baddi, Himachal Pradesh, India, NDA 33342-176-09
- Lots / codes
Lot# BPA5903A, EXP 05/2021; BPA5819A, EXP 11/2020
- Quantity
- 4694 30x60-count bottles
- Company
- Macleods Pharma Usa Inc, Plainsboro, NJ
- Distribution
- Nationwide
- Initiated
- January 24, 2020 · Voluntary: Firm initiated
- Classified
- February 11, 2020
- Reported
- February 12, 2020
- Ended
- December 16, 2022
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Metformin / pioglitazone
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.